A long-term survivor female patient with metastatic melanoma after treatment with pembrolizumab in the third line
2020
Abstract
In recent years, there has been a significant increase in the survival of patients with metastatic malignant melanoma owing to modern immunotherapy using antibodies against immune checkpoints and the introduction of targeted therapy with BRAF and MEK inhibitors. The first antibody used was the anti-CTLA4 antibody ipilimumab which was followed by more effective anti-PD1 antibodies (nivolumab, pembrolizumab); most recently, anti-PD-L1 antibodies have been tested.
An even better therapeutic response has been confirmed by the results of clinical trials investigating combinations of individual antibodies and combinations of antibodies with targeted therapy.